drugset
drugset / Trial / NCT01392469

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469 ↗

Phase 3 Completed 21 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.

Timeline

Start
2011-04-20
Primary completion
2012-10-25
Completion
2012-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 125 mg Oral
Subject Imatinib Small molecule 200 mg Oral
Subject Imatinib Small molecule 400 mg Oral
Subject Sildenafil Unknown 20 mg Oral
Subject Sildenafil Unknown 40 mg Oral
Subject Sildenafil Unknown 50 mg Oral
Subject Sildenafil Unknown 60 mg Oral

Indications

pulmonary arterial hypertension